Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

The first immune checkpoint inhibitor that can be administered via subcutaneous injection in just 1 to 2 minutes has emerged. Alteogen announced on the 20th that its partner Merck (MSD) in the U.S.

Nov 19 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its ...

Keytruda, a Merck cancer immunotherapy that has become the world’s top-selling medication, is administered as an intravenous infusion over the course of 30 minutes. The pharmaceutical giant now has ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...

A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical ...

The FDA approved Merck's proposed method of administering its Keytruda cancer drug by injection rather than intravenous. Merck said Friday the injection, called Keytruda Qlex, has shown comparable ...

This marks the approval of the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered by a health care provider in as little as one minute “We are honored to ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...